HB1336 is a Colorado health-care and pharmacy access bill that expands the role of pharmacists and pharmacy personnel in providing and supporting certain health-care services. It requires health benefit plans, with limited exceptions, to cover pharmacist-provided services when those services are within a pharmacist’s scope of practice and provided under an applicable treatment protocol. The bill also adds new definitions and authorizations in the pharmacy practice statutes, including “final product verification,” and expands the circumstances under which pharmacists may exercise independent prescriptive authority for certain non-controlled substances and FDA-approved products.
The bill further authorizes supervising pharmacists to delegate specified final product verification and related processing tasks to pharmacy technicians or interns under defined conditions, while requiring quality-assessment systems, program plans, and board rules by December 31, 2026. It also updates Medicaid reimbursement law so pharmacists may be reimbursed for medically necessary services within their scope of practice that are not duplicative of other reimbursed services. The measure is intended to increase access to pharmacy services, especially in health professional shortage areas and for certain limited-condition treatment pathways.
Impact
HB1336 amends Colorado insurance, pharmacy practice, and Medicaid reimbursement statutes. It changes section 10-16-144 to require coverage for pharmacist-provided health-care services under qualifying treatment protocols and to prohibit discrimination against pharmacists in participation, referral, reimbursement, and provider network membership solely because of licensure type, while preserving carrier discretion over network design, quality controls, and covered services. It also expands article 280 of title 12 by defining final product verification, authorizing additional pharmacist prescriptive authority for certain age groups and conditions, and allowing delegation of some verification tasks to technicians and interns subject to board rules. Finally, it revises the medical assistance program to allow reimbursement for pharmacist services within scope of practice.
Sentiment
The bill appears to have broad overall support, reflected in strong committee and floor votes in both chambers and a unanimous Senate Health & Human Services committee recommendation to place it on the consent calendar. The House and Senate both passed the measure by comfortable margins, and the House later concurred in the Senate amendments. The voting pattern suggests general agreement with the bill’s goal of expanding access to pharmacy services and using pharmacists more fully in the health-care system.
Contention
The main points of contention centered on how far to expand pharmacist authority and how much to constrain health plans and pharmacies. Failed House committee amendments indicate some disagreement over the scope of the bill’s provisions, likely including the balance between access and regulatory or operational limits. The bill preserves insurer and carrier authority to manage networks and costs, which suggests concern about overmandating participation or coverage, while the technician-delegation and independent-prescribing provisions imply some stakeholders may have been cautious about patient safety, supervision, and liability. Despite those issues, the final votes show that objections were limited and did not prevent passage.